Inhibition of amyloid fiber assembly by both BiP and its target peptide

Immunity

Volumn 13, Issue 4, 2000, Pages 433-442

  Davis, David P ^a   Raffen, Rosemarie ^b   Dul, Jeanne L ^a   Vogen, Shawn M ^a   Williamson, Edward K ^a   Stevens, Fred J ^b   Argon, Yair ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GENE PRODUCT; GLUCOSE REGULATED PROTEIN 78; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANIMAL CELL; ARTICLE; CELL LINE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; MONKEY; MULTIPLE ORGAN FAILURE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CONFORMATION; SOMATIC MUTATION;

EID: 0033715831     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)00043-1     Document Type: Article

References (51)

1. 3D domain swapping: A mechanism for oligomer assembly
2. Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP
3. Peptide-dependent stimulation of the ATPase activity of the molecular chaperone BiP is the result of conversion of oligomers to active monomers
4. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
5. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis
6. BiP and Sec63p are required for both co- and posttranslational protein translocation into the yeast endoplasmic reticulum
7. The requirement for molecular chaperones during endoplasmic reticulum-associated protein degradation demonstrates that protein export and import are mechanistically distinct
8. The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes
9. Monoclonal immunoglobulin deposition disease: Light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis clinical features, immunopathology, and molecular analysis
10. Mapping the major interaction between BiP and immunoglobulin light chains to sites within the variable domain
11. Amyotrephic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase
12. Overrepresentation of the V kappa IV subgroup in light chain deposition disease
13. A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion
14. Identification of a regulatory motif in Hsp70 that affects ATPase activity, substrate binding and interaction with HDJ-1
15. Interconversion of three differentially modified and assembled forms of BiP
16. Binding sites for Hsp70 molecular chaperones in natural proteins
17. BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation
18. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
19. Inhibition of immunoglobulin folding and secretion by dominant negative BiP ATPase mutants
20. Comparison of crystal structures of two homologous proteins: Structural origin of altered domain interactions in immunoglobulin light-chain dimers
21. The V kappa genes of the L regions and the repertoire of V kappa gene sequences in the human germ line
22. Amyloid fibril formation in the rough endoplasmic reticulum of plasma cells from a patient with localized A lambda amyloidosis
23. Aggresomes: A cellular response to misfolded proteins
24. A complex of glycoproteins is associated with VpreB/lambda 5 surrogate light chain on the surface of mu heavy chain-negative early precursor B cell lines
25. Transthyretin quatemary and tertiary structural changes facilitate misassembly into amyloid
26. Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation
27. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
28. Cell-free formation of protease-resistant prion protein
29. Association of transport-defective light chains with immunoglobulin heavy chain binding protein
30. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum
31. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
32. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
33. A domain flip as a result of a single amino-acid substitution
34. From computer simulations to human disease: Emerging themes in protein folding
35. Reengineering immunoglobulin domain interactions by introduction of charged residues
36. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains
37. Synthesis of excess light chains of gamma globulin by rabbit lymph node cells
38. The variable domain of nonassembled Ig light chains determines both their half-life and binding to the chaperone BiP
39. Light chain-associated amyloid deposits comprised of a novel kappa constant domain
40. Beta-sheet breaker peptides inhibit fibrillo-genesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
41. Pathogenic light chains and the B-cell repertoire
42. Protein folding in the ER
43. Structural bases of light chain-related pathology
44. Kinetics of peptide binding to the bovine 70kD heat shock cognate protein
45. Arrest of beta-amyloid fibril formation by a pentapeptide ligand
46. Maintenance and inheritance of yeast prions
47. In vitro dissociation of BiP-peptide complexes requires a conformational change in BiP after ATP binding but does not require ATP hydrolysis
48. Domain stability in immunoglobulin light chain deposition disorders
49. Membrane biogenesis during B cell differentiation: Most endoplasmic reticulum proteins are expressed coordinately
50. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins
51. Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ